Cilastatin: A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.Dipeptidases: EXOPEPTIDASES that specifically act on dipeptides. EC 3.4.13.Thienamycins: Beta-lactam antibiotics that differ from PENICILLINS in having the thiazolidine sulfur atom replaced by carbon, the sulfur then becoming the first atom in the side chain. They are unstable chemically, but have a very broad antibacterial spectrum. Thienamycin and its more stable derivatives are proposed for use in combinations with enzyme inhibitors.CyclopropanesDrug Combinations: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.Protease Inhibitors: Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES).Sulbactam: A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.Carbapenems: A group of beta-lactam antibiotics in which the sulfur atom in the thiazolidine ring of the penicillin molecule is replaced by a carbon atom. THIENAMYCINS are a subgroup of carbapenems which have a sulfur atom as the first constituent of the side chain.Bacterial Infections: Infections by bacteria, general or unspecified.Anti-Bacterial Agents: Substances that reduce the growth or reproduction of BACTERIA.Encyclopedias as Topic: Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)Genitalia, Female: The female reproductive organs. The external organs include the VULVA; BARTHOLIN'S GLANDS; and CLITORIS. The internal organs include the VAGINA; UTERUS; OVARY; and FALLOPIAN TUBES.Library Services: Services offered to the library user. They include reference and circulation.Calcium Oxalate: The calcium salt of oxalic acid, occurring in the urine as crystals and in certain calculi.Biological Products: Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.LebanonMarketing: Activity involved in transfer of goods from producer to consumer or in the exchange of services.Research Report: Detailed account or statement or formal record of data resulting from empirical inquiry.Metabolome: The dynamic collection of metabolites which represent a cell's or organism's net metabolic response to current conditions.Unithiol: A chelating agent used as an antidote to heavy metal poisoning.Diethyl Pyrocarbonate: Preservative for wines, soft drinks, and fruit juices and a gentle esterifying agent.Metabolomics: The systematic identification and quantitation of all the metabolic products of a cell, tissue, organ, or organism under varying conditions. The METABOLOME of a cell or organism is a dynamic collection of metabolites which represent its net response to current conditions.Organophosphonates: Carbon-containing phosphonic acid compounds. Included under this heading are compounds that have carbon bound to either OXYGEN atom or the PHOSPHOROUS atom of the (P=O)O2 structure.Indican: A substance occurring in the urine of mammals and also in blood plasma as the normal metabolite of tryptophan. An increased urinary excretion of indican is seen in Hartnup disease from the bacterial degradation of unabsorbed tryptophan.Levofloxacin: The L-isomer of Ofloxacin.Pneumonia: Infection of the lung often accompanied by inflammation.Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.Anti-Infective Agents: Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection.Cross Infection: Any infection which a patient contracts in a health-care institution.Pneumonia, Bacterial: Inflammation of the lung parenchyma that is caused by bacterial infections.Prescription Drugs: Drugs that cannot be sold legally without a prescription.Insurance, Pharmaceutical Services: Insurance providing for payment of services rendered by the pharmacist. Services include the preparation and distribution of medical products.Drug Prescriptions: Directions written for the obtaining and use of DRUGS.Prescriptions: Directions written for the obtaining and use of PHARMACEUTICAL PREPARATIONS; MEDICAL DEVICES; corrective LENSES; and a variety of other medical remedies.Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Medical Assistance: Financing of medical care provided to public assistance recipients.Monomethylhydrazine: Hydrazine substituted by one methyl group.Ligands: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)Enterobacter: Gram-negative gas-producing rods found in feces of humans and other animals, sewage, soil, water, and dairy products.Enterobacter cloacae: A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in water, sewage, soil, meat, hospital environments, and on the skin and in the intestinal tract of man and animals as a commensal.Urinary Tract Infections: Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.Respiratory Tract Infections: Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.OsteomyelitisEnterobacter aerogenes: Gram-negative, capsulated, gas-producing rods found widely in nature. Both motile and non-motile strains exist. The species is closely related to KLEBSIELLA PNEUMONIAE and is frequently associated with nosocomial infectionsArthritis, Infectious: Arthritis caused by BACTERIA; RICKETTSIA; MYCOPLASMA; VIRUSES; FUNGI; or PARASITES.Systemic Inflammatory Response Syndrome: A systemic inflammatory response to a variety of clinical insults, characterized by two or more of the following conditions: (1) fever >38 degrees C or HYPOTHERMIA 90 beat/minute; (3) tachypnea >24 breaths/minute; (4) LEUKOCYTOSIS >12,000 cells/cubic mm or 10% immature forms. While usually related to infection, SIRS can also be associated with noninfectious insults such as TRAUMA; BURNS; or PANCREATITIS. If infection is involved, a patient with SIRS is said to have SEPSIS.Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include, but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.Multiple Organ Failure: A progressive condition usually characterized by combined failure of several organs such as the lungs, liver, kidney, along with some clotting mechanisms, usually postinjury or postoperative.Calcitonin: A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.Systematized Nomenclature of Medicine: Controlled vocabulary of clinical terms produced by the International Health Terminology Standards Development Organisation (IHTSDO).

Multiple roles for IL-12 in a model of acute septic peritonitis. (1/118)

The present study addressed the role of IL-12 in a murine model of septic peritonitis, induced by cecal ligation and puncture (CLP). Although CLP surgery induced IL-12 production at 6 and 24 h after surgery, IL-12 immunoneutralization was clearly deleterious in this model: 54% of CLP mice receiving preimmune serum survived, whereas mice administered IL-12 antisera prior to CLP experienced a 25% survival rate. IL-12 immunoneutralization not only led to increased mortality, but also appeared to promote a shift away from IL-12 and IFN-gamma, in favor of IL-10. This cytokine shift corresponded to changes in bacterial load, as CLP mice receiving IL-12 antiserum yielded more CFUs from the peritoneal cavity at 24 h after CLP. To address the role of bacterial infection in IL-12 antiserum-induced mortality following CLP, antibiotics were administered for 4 days after surgery. Despite regular antibiotic administration, IL-12 immunoneutralization still reduced survival in CLP mice. Furthermore, histology of the ceca revealed that mice administered IL-12 antisera failed to show typical organization of the damaged cecum wall. Accordingly, Gram staining revealed bacteria within peritoneal fluids from these mice, while peritoneal fluids from CLP mice that received preimmune serum and antibiotics were free of bacteria. Altogether, these data suggested multiple important roles for IL-12 in the evolution of murine septic peritonitis.  (+info)

Effects of antibiotic therapy on Pseudomonas aeruginosa-induced lung injury in a rat model. (2/118)

The effect of antibiotics on the acute lung injury induced by virulent Pseudomonas aeruginosa PA103 was quantitatively analyzed in a rat model. Lung injury was induced by the instillation of PA103 directly into the right lower lobes of the lungs of anesthetized rats. The alveolar epithelial injury, extravascular lung water, and total plasma equivalents were measured as separate, independent parameters of acute lung injury. Four hours after the instillation of PA103, all the parameters were increased linearly depending on the dose of P. aeruginosa. Next, we examined the effects of intravenously administered antibiotics on the parameters of acute lung injury in D-galactosamine-sensitized rats. One hour after the rats received 10(7) CFU of PA103, an intravenous bolus injection of aztreonam (60 mg/kg) or imipenem-cilastatin (30 mg/kg) was administered. Despite an MIC indicating resistance, imipenem-cilastatin improved all the measurements of lung injury; in contrast, aztreonam, which had an MIC indicating sensitivity, did not improve any of the lung injury parameters. The antibiotics did not generate different quantities of plasma endotoxin; therefore, endotoxin did not appear to explain the differences in lung injury. This in vivo model is useful to quantitatively compare the efficacies of parenteral antibiotic administration on Pseudomonas airspace infections.  (+info)

Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. (3/118)

DA-1131, a new carbapenem antibiotic, undergoes renal metabolism by renal dehydropeptidase I (DHP-I), located on the brush border of the proximal tubular cell. Species differences with regard to the effects of cilastatin, a renal DHP-I inhibitor, were investigated after a 1-min intravenous infusion of DA-1131, with or without cilastatin, to rats, rabbits, and dogs. After intravenous infusion, the nonrenal clearance (CL(NR)) of DA-1131 was significantly slower in rats (3.00 versus 8.01 ml/min/kg) and rabbits (2.41 versus 6.77 ml/min/kg) when the drug was coadministered with cilastatin; this could be due to the slower metabolism of DA-1131 by rat and rabbit kidney DHP-I. This indicated that renal metabolism of DA-1131 by renal DHP-I was inhibited by cilastatin. However, coadministration with cilastatin to dogs did not affect the CL(NR) of DA-1131.  (+info)

Modification of acquired immunity in mice by imipenem/cilastatin. (4/118)

The immunomodulating properties of antimicrobial drugs may have important implications for clinical practice, particularly for those patients whose immune system has been compromised. In this study, we assessed the influence of different treatments with a beta-lactam antibiotic (imipenem/cilastatin) on several acquired immune responses of BALB/c mice; splenocyte responses to specific mitogens and to sheep red blood cells, IL-2 production and proportions of the different lympho-monocytic populations. Impenem/cilastatin was shown to modify some lymphocyte-associated immune functions and it would be useful to investigate whether immunomodulatory effects also occur in humans.  (+info)

Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. (5/118)

An open, randomized, multinational, multicentre study was conducted to compare the efficacy, safety and tolerability of levofloxacin 500 mg twice daily with imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized adult patients with clinically suspected bacteraemia/ sepsis. Levofloxacin patients could change from iv to oral administration after a minimum of 48 h iv treatment if clinical signs and symptoms of sepsis had improved. The primary efficacy analysis was based on the clinical and bacteriological response at clinical endpoint. A total of 503 patients were randomized and 499 included in the intent-to-treat population. The per-protocol population comprised 287 patients with bacteriologically proven infection. Clinical cure rates at clinical endpoint in the intent-to-treat population and per-protocol population were 77% (184/239) and 89% (125/140), respectively, for levofloxacin and 68% (178/260) and 85% (125/147), respectively, for imipenem/cilastatin. At follow-up, the cure rates in the per-protocol population were 84% for levofloxacin and 69% for imipenem/cilastatin. The 95% confidence interval for both populations showed that levofloxacin was as effective as imipenem/cilastatin. A satisfactory bacteriological response was obtained in 87% (96/110) of levofloxacin patients and 84% (97/116) of imipenem/cilastatin patients at clinical endpoint. Adverse events possibly related to the study drug were reported in 74 (31%) levofloxacin patients and 79 (30%) imipenem/cilastatin patients. There were no clinically appreciable differences between the treatment groups. Levofloxacin 500 mg twice daily, either iv or as sequential iv/oral therapy, was as effective and well tolerated as imipenem/cilastatin 1 g iv three-times daily in the treatment of hospitalized patients with suspected bacteraemia/sepsis.  (+info)

Molecular homology and the luminal transport of Hg2+ in the renal proximal tubule. (6/118)

The aim of this study was to define mechanisms involved in the luminal uptake of inorganic mercury in the kidney using isolated perfused straight (S2) segments of the proximal tubule. When mercuric conjugates of glutathione (GSH), cysteinylglycine. or cysteine (containing 203Hg2+) were perfused through the lumen, the rates of luminal disappearance flux (JD) of inorganic mercury were approximately 39, 53, and 102 fmol/min per' min, respectively. Thus, the rates of luminal uptake of mercury are greater when the mercury is in the form of a mercuric conjugate of cysteine than in the form of a mercuric conjugate of cysteinylglycine or GSH. Addition of acivicin to the perfusate, to inhibit activity of the y-glutamyltransferase, caused significant reductions in the J,, for mercury in tubules perfused with mercuric conjugates of GSH. Addition of cilastatin, an inhibitor of dehydropeptidase- l (cysteinylglycinase) activity, caused significant reductions in the uptake of mercury in tubules perfused with mercuric conjugates of cysteinylglycine. These findings indicate that a significant amount of the luminal uptake of mercury, when mercuric conjugates of GSH are present in the lumen, is dependent on the activity of both y-glutamyltransferase and cysteinylglycinase. Finally, the JD for mercury in tubules perfused with mercuric conjugates of cysteine was reduced by approximately 50% when 3.0 mM L-lysine or 5.0 mM cycloleucine was added to the perfusate. It is concluded that these findings indicate that at least some of the luminal uptake of mercuric conjugates of cysteine occurs at the site of one or more amino acid transporters via a mechanism involving molecular homology.  (+info)

Acute necrotizing pancreatitis: treatment strategy according to the status of infection. (7/118)

OBJECTIVE: To determine benefits of conservative versus surgical treatment in patients with necrotizing pancreatitis. SUMMARY BACKGROUND DATA: Infection of pancreatic necrosis is the most important risk factor contributing to death in severe acute pancreatitis, and it is generally accepted that infected pancreatic necrosis should be managed surgically. In contrast, the management of sterile pancreatic necrosis accompanied by organ failure is controversial. Recent clinical experience has provided evidence that conservative management of sterile pancreatic necrosis including early antibiotic administration seems promising. METHODS: A prospective single-center trial evaluated the role of nonsurgical management including early antibiotic treatment in patients with necrotizing pancreatitis. Pancreatic infection, if confirmed by fine-needle aspiration, was considered an indication for surgery, whereas patients without signs of pancreatic infection were treated without surgery. RESULTS: Between January 1994 and June 1999, 204 consecutive patients with acute pancreatitis were recruited. Eighty-six (42%) had necrotizing disease, of whom 57 (66%) had sterile and 29 (34%) infected necrosis. Patients with infected necrosis had more organ failures and a greater extent of necrosis compared with those with sterile necrosis. When early antibiotic treatment was used in all patients with necrotizing pancreatitis (imipenem/cilastatin), the characteristics of pancreatic infection changed to predominantly gram-positive and fungal infections. Fine-needle aspiration showed a sensitivity of 96% for detecting pancreatic infection. The death rate was 1.8% (1/56) in patients with sterile necrosis managed without surgery versus 24% (7/29) in patients with infected necrosis (P <.01). Two patients whose infected necrosis could not be diagnosed in a timely fashion died while receiving nonsurgical treatment. Thus, an intent-to-treat analysis (nonsurgical vs. surgical treatment) revealed a death rate of 5% (3/58) with conservative management versus 21% (6/28) with surgery. CONCLUSIONS: These results support nonsurgical management, including early antibiotic treatment, in patients with sterile pancreatic necrosis. Patients with infected necrosis still represent a high-risk group in severe acute pancreatitis, and for them surgical treatment seems preferable.  (+info)

Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin. (8/118)

BACKGROUND: A prospective multicentre study was undertaken to compare the efficacy of intravenous ciprofloxacin or imipenem in the treatment of severe nosocomial pneumonia requiring mechanical ventilation. METHODS: Patients with a clinical suspicion of pneumonia were randomised to receive either ciprofloxacin (800-1200 mg/day) or imipenem (2-4 g/day) in doses adjusted for renal function and specimens of the lower respiratory tract were taken. Patients were included in the study when specimens showed significant growth for potentially pathogenic microorganisms in quantitative bacterial cultures (n = 75, ciprofloxacin 41/75 (55%); imipenem 34/75 (45%)). The clinical and bacteriological success rates were the primary and secondary efficacy variables. An intent-to-treat analysis was performed for all randomised patients who received at least one dose of the study medication (n = 149, ciprofloxacin 72/149 (48%), imipenem 77/149 (52%)). RESULTS: The success rates were generally good, but neither the clinical success rates (ciprofloxacin, 29/41 (71%), imipenem, 27/34 (79%); 95% CI -10.8 to 28.1; p = 0.435) nor the bacteriological response rate (ciprofloxacin, 20/41 (49%), imipenem, 17/34 (50%); 95% CI -21.5 to 23.9; p = 1.0) were significantly different between the study arms. Pseudomonas aeruginosa was recovered in 26/75 patients (35%) and clinical (ciprofloxacin, 10/14 (71%), imipenem, 8/12 (67%); 95% CI -40.4 to 30.9; p = 1.0) and bacteriological response rates (ciprofloxacin, 7/14 (50%), imipenem, 3/12 (25%), 95% CI -60.9 to 10.9, p = 0.247) were not significantly different in this subgroup of patients. Resistance of Pseudomonas aeruginosa developed in 5/26 cases (19%), 1/14 (7%) to ciprofloxacin and 4/12 (33%) to imipenem (p = 0.147), and the mortality was 12/75 (16%) with no difference between treatment groups (ciprofloxacin, 8/41(24%), imipenem 4/34 (17%); p = 0.362). The clinical response was evaluable in 109/149 patients (73%) in the intent-to-treat analysis and was successful in 74/109 patients (68%). The clinical response rates were also not significantly different in the intent-to-treat analysis (ciprofloxacin, 34/52 (65%), imipenem, 40/57 (70%); 95% CI -12.8 to 22.3; p = 0.746). CONCLUSIONS: Treatment with either ciprofloxacin or imipenem was effective in a selected group of patients with microbiologically confirmed, severe nosocomial pneumonia requiring mechanical ventilation. Although no differences between the study medication could be documented in this trial, smaller differences between treatment arms may have been missed because of sample size limitations.  (+info)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital Wissam K Kabbara, George T Nawas, Wijdan H RamadanDepartment of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos, Lebanon Background: Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. Methods: This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem
Despite advances in prevention and treatment, hospital-acquired pneumonia remains a significant problem as the second most common infection acquired in the hospital and the most deadly (20%-50% of patients who acquire pneumonia while in the hospital die from complications of pneumonia). Levofloxacin has been shown in clinical trials to be effective against a number of different bacteria, including those found to be common and uncommon causes of pneumonia. This multicenter, open-label study evaluates the safety and effectiveness of levofloxacin as compared with imipenem/cilastatin, another type of antibiotic treatment, in patients with pneumonia acquired in the hospital. Patients receive treatment for a total of 7-15 days, initially with levofloxacin or imipenem/cilastatin, administered slowly through a vein. If patients respond positively to either drug, treatment may be changed to levofloxacin or ciprofloxacin (if initially treated with imipenem/cilastatin), to be taken by mouth. Certain ...
Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is an enzyme found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin can therefore be combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect. Imipenem alone is an effective antibiotic and can be given without the cilastatin. Cilastatin itself does not have antibiotic activity although it has been proved to be active against a zinc-dependent beta-lactamase that usually confer antibiotic resistance to certain bacteria; more precisely the carbapenem family of antibiotics. This property is due to the physico-chemical similarities between membrane dipeptidase (MDP), the compound it is usually set to target, and the bacterial metallo-beta-lactamase carried by the CphA gene Therefore, cilastatin is considered a beta-lactamase inhibitor, not an antibiotic per se. But as with other combinations of an ...
Imipenem/cilastatin has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage.[11] Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. Imipenem/cilastatin, like other carbapenems, binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. It has activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, S. agalactiae, S. ...
Cilastatin; Imipenem information about active ingredients, pharmaceutical forms and doses by Jodas Expoim, Cilastatin; Imipenem indications, usages and related health products lists
QUEPREON BIOLOGICALS PVT LTD. - Manufacturer & Supplier of Imipenem Cilastatin For Injection Usp 250 Mg based in Bengaluru, India
The report generally describes cilastatin sodium, examines its uses, production methods, patents. CILASTATIN SODIUM market situation is overviewed;
Imipenem is an antibiotic that fights bacteria. Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach, or female reproductive organs...
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
PRIMAXIN IM 500 (Cilastatin sodium,Imipenem) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
The IUPHAR/BPS Guide to Pharmacology. cilastatin ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
Buy Best Prescription Drugs Available Online with FDA Approved Prescription Medications. Our goal is to provide you with the best value on prescription drugs & use our personal prescription system which ultimately leads you to live longer and healthier life.
Lemibet I.V. information about active ingredients, pharmaceutical forms and doses by Teva, Lemibet I.V. indications, usages and related health products lists
Imipenem, the first clinically used carbapenem, was developed at Merck and Co. It was approved for use in the United States in 1985.[20] Imipenem is hydrolyzed in the mammalian kidney by a dehydropeptidase enzyme to a nephrotoxic intermediate, and thus is co-formulated with the dehydropeptidase inhibitor cilastatin.[5] Imipenem is available in both intravenous[21] and intramuscular[22] formulations.. Meropenem is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for use in the United States in 1996. In most indications it is somewhat more convenient to administer than imipenem, 3 times a day rather than 4. Doses of less than one gram may be administered as an IV bolus, whereas imipenem is usually administered as a 20-minute to one hour infusion. Meropenem is somewhat less potent than imipenem against gram-positive pathogens, and somewhat more potent against gram-negative infections. Unlike imipenem, which produced an unacceptable rate of ...
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS). Mediates the sodium-independent uptake of p- aminohippurate (PAH), ochratoxin (OTA), acyclovir (ACV), 3-azido- 3-deoxythymidine (AZT), cimetidine (CMD), 2,4-dichloro- phenoxyacetate (2,4-D), hippurate (HA), indoleacetate (IA), indoxyl sulfate (IS) and 3-carboxy-4-methyl-5-propyl-2- furanpropionate (CMPF), cidofovir, adefovir, 9-(2- phosphonylmethoxyethyl) guanine (PMEG), 9-(2- phosphonylmethoxyethyl) diaminopurine (PMEDAP) and edaravone sulfate. PAH uptake is inhibited by p- chloromercuribenzenesulphonate (PCMBS), diethyl pyrocarbonate (DEPC), sulindac, diclofenac, carprofen, glutarate and okadaic acid. PAH uptake is inhibited by ...
He didnt offer his wife consolation, ciplox ear drops price particularly or apologize that they died in his care? I intelligently benadryl price always carry a few Kind Bars in my bag, because theyre a great snack made with whole foods, and have nothing artificial. 23, sporanox cost 25 There have been reports of worsening of myasthenia with the use of imipenem/cilastatin, 54 and with infusion of vancomycin. However, sporanox cost most evidence for these roles comes from in vitro, animal, and epidemiological studies, not the randomized clinical trials considered to be more definitive [ 1]! Du moins cest ainsi en milieu hospitalier, ds les centres anti douleur etc! Even effexor cost negligently less likely to feel shame upon an incident of abnormality. Jos unohdat ottaa annoksen, ota se heti kun muistat asian, jollei ole jo seuraavan annoksen aika? 7 These guidelines list observation as an option for children older than six months; observation involves deferring antibiotic treatment for 48 to ...
10 下列抗生素中,何者容易被renal tubular dehydropeptidase 破壞,所以常併用cilastatin 來抑制此酵素,以提高此抗生素在血中之濃度 ...
Wide spectrum action against aerobes & anaerobes More active than ceftazidime Wide spectrum of action including gram +ve & gram-ye coverage Cilastatin diminishes adverse reaction associated with imipenem administration   Dosage : Adults : In terms of Impenem ,1.2 g Daily in Divided Doses every 6-8 Irs given Via I.V. infusion Children : 3WS 15-25 mg/Kg Every 6 Hrs by IV Infusion Surgical Prophylaxis In Terms of Impenem 19 given on induction of anaesthesia followed by 1g 3 Hrs Later   Indications : Infections In Dialysis Patients  UT Infections  LRT Infections  Endocarditis  Gynaecological Infection  Diabetic Foot Infection  Intra Abdominal Infection  Bone & Joint Infections  Skin & Skin Structure Infection  Nosocomial ...
Tissue distribution of the drug (therapeutic concen- neonates with poor aminoglycoside kinetics or docu- trations must be reached at the site of infection) mented multiresistant infections, and the drug shouldbe administered at 11 mg/kg IV or IM q8h. A new class Foals with pneumonia secondary to septicemia require of synthetic β-lactams, the carbapenems, exhibits a high broad-spectrum therapy because of either gram-nega- degree of stability in the presence of β-lactamases and tive or gram-positive involvement. Older foals with may be useful in critically ill foals with documented uncomplicated pneumonia may initially be treated with multiresistant infections. Imipenem-cilastatin has been a gram-positive regimen, but a poor response to treat- used in foals at an empiric dosage of 5 to 10 mg/kg IM ment represents a clear indication for institution of bid with apparent safety and efficacy.6 Intravenous broad-spectrum therapy. Evidence of pulmonar y administration substantially increases the ...
Lumene Time Freeze Anti-Age Color Correcting CC Cream: rated 4.2 out of 5 on MakeupAlley. See 20 member reviews, ingredients and photo. filter: reviewer hair type Wavy
Cilastatin: FDA approves Tygacil for the treatment of complicated skin and skin structure infections. Health and Medicine Reference Covering Thousands of Diseases and Prescription Drugs.
Tigecycline is FDA approved in patients 18 years of age or older for the treatment of complicated skin and skin structure infections (SSSI) caused by susceptible organisms, including methicillin-resistant Staphylococcus aureus and vancomycin sensitive Enterococcus faecalis. In addition, it is indicated for the treatment of complicated intra-abdominal infections (cIAI) and community-acquired pneumonia (CAP) caused by susceptible organisms.1. To date, tigecycline does not have a place in therapy for hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) due to an increase in mortality that was observed when using tigecycline in these conditions. A search of the medical literature returned several supportive studies.. Freire, et al. (2010) conducted a phase 3, randomized, double-blind trial comparing tigecycline with imipenem/cilastatin for the treatment of HAP.2 Patients were given an initial dose of 100 mg IV, followed by 50 mg IV every 12 hours. The tigecycline regimen was ...
CD199 (CCR9) Mouse anti-Mouse, APC, Clone: CW-1.2, eBioscience™ 25μg; APC CD199 (CCR9) Mouse anti-Mouse, APC, Clone: CW-1.2, eBioscience™ Primary...
The Nutshell EPO Revokes Broads CRISPR Patent Shortly after ruling out the earliest priority dates on a foundational patent for CRISPR gene-editing technology, the European Patent Office rescinded the patent entirely-and more are likely to follow.. ...
The risk of pregnancy increases with each. Ampicillin and Sulbactam and aminoglycosides should not be reconstituted together due to the in vitro inactivation of.Is ampicillin safe in pregnancy. Talk to your doctor about any side effect that seems unusual or. Ceftriaxone attenuates alcohol intake take it Tell your level.1. Chemical and Physical Data 1.1 Synonyms ehem. clavulanic acid and sulbactam (Foulds, 1986;. The disposition of ampicilln is altered in pregnancy.. IC Fertility Pregnancy Immunochemistry Fertility/Pr Pregnanc. AMPICILLIN AM 256 WW S30. SULBACTAM SUL 256 WW S30.Ampicillin sulbactam can be used as. Which organ made during pregnancy provides nutrients to and removes wastes from the fetus as well as producing hormones.Pregnancy cat. B Appears safe in pregnancy [1] Legal status. Co-amoxiclav (Amoxicillin/clavulanic acid) 1 · Imipenem/cilastatin 1 · Ampicillin/sulbactam.wh0cd594755 ,a href=http://ampicillinsulbactam.review/,ampicillin sulbactam. Women need to take their ...
387552322 - EP 1113016 A4 2001-12-12 - CARBAPENEM COMPOUNDS - [origin: WO0015640A1] Carbapenem compounds represented by general formula (I); pharmacologically acceptable salts of the same; and antibacterial agents containing these compounds or salts as the active ingredient (wherein R is hydrogen or optionally substituted lower alkyl; and n is an integer of 1 or 2). The compounds and salts exhibit a potent antibacterial activity and are excellent in the resistance to beta -lactamase and renal dehydropeptidase.[origin: WO0015640A1] Carbapenem compounds represented by general formula (I); pharmacologically acceptable salts of the same; and antibacterial agents containing these compounds or salts as the active ingredient (wherein R is hydrogen or optionally substituted lower alkyl; and n is an integer of 1 or 2). The compounds and salts exhibit a potent antibacterial activity and are excellent in the resistance to beta -lactamase and renal dehydropeptidase.
BioAssay record AID 56107 submitted by ChEMBL: Stability towards hog kidney dehydropeptidase (DHP) expressed as relative hydrolysis to imipenem.
CD199 (CCR9), PE-Cyanine7, clone: eBioCW-1.2 (CW-1.2), eBioscience™ 100μg; PE-Cyanine7 CD199 (CCR9), PE-Cyanine7, clone: eBioCW-1.2 (CW-1.2),...
Press Release issued Aug 28, 2014: Reportstack, provider of premium market research reports announces the addition of Complicated Intra-Abdominal Infections - Pipeline Review, H2 2014 market report to its offering
About XERAVATM XERAVA(eravacycline for injection) is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA was investigated for the treatment of cIAI as part of the Companys IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) Phase 3 program. In the first pivotal Phase 3 trial in patients with cIAI, twice-daily intravenous (IV) XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to ertapenem and was well-tolerated. In the second Phase 3 clinical trial in patients with cIAI, twice-daily IV XERAVA met the primary endpoint by demonstrating statistical non-inferiority of clinical response compared to meropenem and was well-tolerated. In both trials, XERAVA achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. Indications and Usage XERAVA is indicated for the treatment of ...
05 (P < 0.05). Multivariate analysis will be carried out by means of stepwise logistic regressions in order to assess the predictive factors of mortality during hospitalization. Adjusted odds ratios (OR) and their 95% confidence intervals (CI) will also be included. Inclusion criteria MG-132 nmr patients older than 18 years Community- and healthcare-acquired complicated intra-abdominal infections Exclusion criteria Age. under 18 years old Pancreatitis Primary peritonitis. Preliminary results Patients This preliminary report includes all data from the first two months of the six-month study period. 702 patients with a mean age of 49.2 years (range 18-98) were enrolled in the study. 272 patients (38.7%) were women and 430 (62.3%) were men. Among these patients, 615 (87.6%) were affected by community-acquired IAIs while the remaining 87 (12.4%) suffered from healthcare-associated infections. 304 patients (43.3%) were affected by generalized peritonitis while. 398 (57.7%) suffered Selleckchem ...
Polyphor Announces Successful End Of Phase II Meeting With FDA For Murepavadin In Nosocomial Pneumonia - read this article along with other careers information, tips and advice on BioSpace
Anti-CCR9 antibody conjugated to Phycoerythrin [CW-1.2] validated for Flow Cyt and tested in Mouse and Rat. Referenced in 1 publication and 5 independent…
Dipeptide mimics which contain phosphorus and their pharmaceutical use and preparation are disclosed. The compounds have dehydropeptidase (DHP) enzyme inhibitor activity.
Meets all industry-wide current halogen-free and halide-free requirements. Most mildly activated of the Ultra-Clear Series. Made with ultra-clear modified rosins. ...
For this, the Hospital-acquired Pneumonia Drugs Market report covers the company overview, financial metrics, tactics, business strategies, trends, acquisitions, and merger of the key participants active in the global Hospital-acquired Pneumonia Drugs Market. Further, the analysis offers a thorough evaluation of the latest key trends and technologies playing an imperative part in the Hospital-acquired Pneumonia Drugs Market growth.. Hospital-acquired Pneumonia Drugs Market includes identifying and comparing major competitors such as Pfizer, GlaxoSmithKline, Merck, Mylan, Novartis, Teva Pharmaceutical Industries, AstraZeneca, Arsanis, Combioxin, Shinogi, Sun Pharmaceutical Industries, The Medicines Company, Theravance Biopharma. The market can be segmented into Product Types as - Antibacterial, Antiviral, Antifungal. The market can be segmented into Applications as - Hospitals, Clinics, Other. The Regional Focused Zone Includes:-. * The Middle East and Africa Hospital-acquired Pneumonia Drugs ...
Overview Problem: Hospital-acquired pneumonia (HAP) is the second most common nosocomial infection and is a significant cause of morbidity and mortality. In the surgical population, HAP is associated with a 55% increase in length of stay and increased costs of approximately $31,000.00 per case. Neurologically impaired patients (those with brain injury causing alterations in mental status, immobility, impaired swallowing and cough, and increased risk of aspiration) are particularly vulnerable to HAP. HAP negatively impacts patient comfort and satisfaction, increases costs associated with diagnostic tests and treatments, increases risk for sepsis, and potential for higher level of care. It is estimated 95% of care-dependent patients on the Royal Columbian Hospital (RCH) neuroscience unit acquire HAP during their stay.. Gap: Research studies have shown improving oral hygiene in critical care, neuroscience intensive care units and cardiac surgery reduces the incidence of HAP. However, in the acutely ...
Activity comparable to an activated rosin flux and is recommended primarily for hard to solder assemblies including metals such as oxidized copper, nickel, brass and beryllium-copper. The residue left after soldering is non-corrosive and non-conductive. Even with this higher activity, CW-219 passes J-STD-004B, SIR, and ECM requirements.Activity comparable to an activated rosin flux and is recommended primarily for hard to solder assemblies including metals such as oxidized copper, nickel, brass and beryllium-copper. The residue left after soldering is non-corrosive and non-conductive. Even with this higher activity, CW-219 passes J-STD-004B, SIR, and ECM requirements. ...
Hospital‑acquired pneumonia increases the length of in-patient hospital stay and is associated with high mortality rates, particularly in older people. Pharmacists and healthcare professionals need to know how to diagnose and manage the condition, and be cognisant of the gaps in the evidence base.
Pneumonia is an important cause of morbidity and mortality in adults with about 5 million cases reported annually in the United States itself.
The success rate of the clinical response to treatment of severe nosocomial pneumonia in patients requiring mechanical ventilation was not significantly different between ciprofloxacin (29/41, 71%) and imipenem (27/34, 79%). This was true for the study population and the intent-to-treat population. No differences were found in the bacterial response rate to ciprofloxacin (20/49, 49%) or imipenem (17/34, 50%) in this study population.. Despite the introduction of potent broad spectrum antimicrobial agents and the use of preventive measures, nosocomial pneumonia remains an important cause of mortality and morbidity in the ICU.1 28 29 The causative microorganism varies according to the individual patient risk profile. The severity, type, and number of risk factors and the time of onset of nosocomial pneumonia may influence the risk profiles. Gram negative bacilli, Enterobacteriaceae,H influenzae, and methicillin sensitiveS aureus are frequent causative agents in nosocomial pneumonia. P aeruginosa ...
The Surgical Infection Society and Infectious Diseases Society of America recently updated recommendations for diagnosis and treatment of intra-abdominal infections. Intra-abdominal infections are the second most common cause of infectious mortality in intensive care units. Complicated intra-abdominal infection, which extends into the peritoneal space, is associated with abscess formation and peritonitis.
Nosocomial pneumonia is the most important infectious complication in patients admitted to intensive care units. Kinetic bed therapy may reduce the incidence of nosocomial pneumonia in mechanically ventilated patients. The objective of this study was to investigate whether kinetic bed therapy reduces the incidence of nosocomial pneumonia and improves outcomes in critically ill mechanically ventilated patients. We searched Medline, EMBASE, CINAHL, CENTRAL, and AMED for studies, as well as reviewed abstracts of conference proceedings, bibliographies of included studies and review articles and contacted the manufacturers of medical beds. Studies included were randomized or pseudo-randomized clinical trials of kinetic bed therapy compared to standard manual turning in critically ill mechanically ventilated adult patients. Two reviewers independently applied the study selection criteria and extracted data regarding study validity, type of bed used, intensity of kinetic therapy, and population under
Nosocomial pneumonia is the most important infectious complication in patients admitted to intensive care units. Kinetic bed therapy may reduce the incidence of nosocomial pneumonia in mechanically ventilated patients. The objective of this study was to investigate whether kinetic bed therapy reduces the incidence of nosocomial pneumonia and improves outcomes in critically ill mechanically ventilated patients. We searched Medline, EMBASE, CINAHL, CENTRAL, and AMED for studies, as well as reviewed abstracts of conference proceedings, bibliographies of included studies and review articles and contacted the manufacturers of medical beds. Studies included were randomized or pseudo-randomized clinical trials of kinetic bed therapy compared to standard manual turning in critically ill mechanically ventilated adult patients. Two reviewers independently applied the study selection criteria and extracted data regarding study validity, type of bed used, intensity of kinetic therapy, and population under
Ceftazidime-avibactam is being developed with Astra Zeneca jointly. Forest Laboratories LLC., a subsidiary of Actavis plc, holds the rights to commercialize ceftazidime-avibactam in North America, while AstraZeneca holds the privileges to commercialize ceftazdime-avibactam in the rest of the global world.. Actavis reports excellent results from ceftazidime-avibactam Phase III studies in cIAI patients Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the prospect of the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized sufferers with complicated intra-abdominal infections. Ceftazidime-avibactam includes a cephalosporin , an established treatment for significant bacterial infections, and a next generation non-beta lactam beta-lactamase inhibitor .This system appears to be more essential than those earlier described for prolonged stimulation by dopamine, as would be the case in those with ...
The WBC count may be normal or elevated in nosocomial pneumonia or disorders that mimic nosocomial pneumonia/ventilator-associated pneumonia (VAP). A left shift reflects the stress and neither rules o... more
Epidemiologie der Beatmungspneumonie Inzidenz: % bzw /1000 Tage VAP-Rate: 1-3 % pro Beatmungstag ICU-Therapie: +6d d Beatmung: +10d d Letalität: % 1 Torres A et.al. Incidence, risk, and prognosis factor of nosocomial pneumonia in mechanically ventilated patients. Am Rev Respir Dis 1990; 142: Hauer T et. al. Nosokomiale Infektionen in Deutschland. Med Klinik 1996; 9: Fagon JY et. al. Nosocomial Pneumonia. in: Schoemaker. Critical Care Medicine. 4th Ed. Philadelphia 2000: Fagon JY, Chastre J, Vuagnat A, Trouillet J-L, Novara A, and Gibert C. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996;275:866-9 George DL, AJRCCM 1998;158:1839 Craven DE, Steger KA. Epidemiology of nosocomial pneumonia. Chest 1995:108:1S-16S Fagon JY et al. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 1996;275:866-9 Cook DJ et al. Incidence of and risk factors for ventilator-associated pneuminoa in critically ill patients. Ann Intern Med 1998;129: Fagon JY et. al.
|div id=teaser class=fragment teaser ||div class=p|Everything NICE has said on diagnosing and managing community- and hospital-acquired pneumonia in adults in an interactive flowchart|/div||/div|
ZOLYD is an investigational, first-in-class injectable epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains that are of particular concern to public health. ZOLYD has a differentiated mechanism of action that acts at an earlier step in cell wall synthesis inhibition, providing activity against pathogens that are often resistant to other classes of antibiotics.. The U.S. Food and Drug Administration (FDA) granted Fast Track designation and Qualified Infectious Disease Product (QIDP) designation for the investigation of ZOLYD for the following indications: cUTI, hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), acute bacterial skin and skin structure infections (ABSSSI), complicated intra-abdominal infections (cIAI). These designations make ZOLYD eligible for certain incentives available for the development of new antibiotics, including priority FDA ...
BULGULAR: Ampirik tedavi olarak 43 hastan n 40 da (%93) antipseudomonal tedavi ba lanmas na ra men en s k izole edilen etkenler Acinetobacter spp ve Escherichia coli idi. Tedavi sonu klinik ba ar oran %65.1 idi. S rvi oranlar 3.,14., 42. ve 365. g n s ras yla % 97, 86, 58 ve 19 olarak bulundu. re y ksekli i [Hazard Ratio=1.01 (%95 GA: 1.00-1.02)] ve kan ekeri y ksekli i [HR=1.01 (%95 GA: 1.00-1.02)] surviyi olumsuz etkileyen ba ms z risk fakt rleri olarak bulundu. N tropenik olmayan (n=23) hastalarda klinik ba ar oranlar n tropenik (n=20) olanlara g re daha y ksek bulundu (p=0.05 ...
Drug Name】. Generic name: Meropenem for injection. Product Name: Double Energy. 【Properties】 This product is white to slightly yellow powder.. [Ingredients] The main ingredient of this product is meropenem.. [Pharmacological action]. This product is a synthetic broad-spectrum carbapenem antibiotic that produces an antibacterial effect by inhibiting the synthesis of bacterial cell walls.. [Indications] Applicable to infections caused by single or multiple meropenem-sensitive bacteria in adults and children.. 【Dosage】. The intravenous infusion of meropenem should be greater than 5 minutes and the intravenous infusion time should be greater than 15 to 30 minutes. The dosage and interval of administration for an adult should be based on the type of infection, the severity, and the specific circumstances of the patient.. [Specification] According to C17H25N3O5S (1) 0.25g (2) 0.5g (3) 1.0g. ...
Disclaimer: Information published on this blog are my opinions and findings the way I understand them. I try to provide good information, but my main goal is to get you to get educated and come to your own understanding of things. ...
Empiric therapeutic regimens for hospital-acquired pneumonia (HAP), health care-associated pneumonia (HCAP), and ventilator-associated pneumonia (VAP) are outlined below, including those for early onset, late onset, and multidrug-resistant (MDR) factors. Definitions HAP: diagnosis made > 48h after admission VAP: diagnosis made 48-72h after ...
Q: Is it appropriate to assign code Y95, nosocomial condition, based on the documentation of healthcare-associated pneumonia (HCAP) or hospital-acquired pneumonia (HAC)? It is appropriate to assign code Y95, nosocomial condition, for documented healthcare associated conditions. Should this still be queried for specificity, and should the HAC condition (i.e. pneumonia) be coded as bacterial, viral, or something else?
Analysis of charges associated with diagnosis of nosocomial pneumonia: can routine bronchoscopy be justified?: Many ventilated trauma patients thought to have n
Looking for online definition of peptidyl dipeptidase A in the Medical Dictionary? peptidyl dipeptidase A explanation free. What is peptidyl dipeptidase A? Meaning of peptidyl dipeptidase A medical term. What does peptidyl dipeptidase A mean?
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder. ...
Physician assistants and nurse practitioners use Clinical Advisor for updated medical guidance to diagnose and treat common medical conditions in daily practice.
severe allergic reactions (rash; hives; itching; trouble breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); bloody or black, tarry stools; change in the amount of urine produced; chest pain; confusion; dark urine; depression; fainting; fast or irregular heartbeat; fever, chills, or persistent sore throat; mental or mood changes; numbness of an arm or leg; one-sided weakness; red, swollen, blistered, or peeling skin; ringing in the ears; seizures; severe headache or dizziness; severe or persistent stomach pain or nausea; severe vomiting; shortness of breath; sudden or unexplained weight gain; swelling of hands, legs, or feet; unusual bruising or bleeding; unusual joint or muscle pain; unusual tiredness or weakness; vision or speech changes; vomit that looks like coffee grounds; yellowing of the skin or eyes ...
Kahan, FM; Kropp, H; Sundelof, JG; Birnbaum, J (Dec 1983). "Thienamycin: development of imipenen-cilastatin". The Journal of ... Buckley, MM; Brogden, RN; Barradell, LB; Goa, KL (1992). "Imipenem/cilastatin. A reappraisal of its antibacterial activity, ... Clissold, SP; Todd, PA; Campoli-Richards, DM (1987). "Imipenem/cilastatin. A review of its antibacterial activity, ... "Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy". Drugs. 33 (3 ...
"Cilastatin/imipenem/relebactam - AdisInsight". Springer International Publishing AG. Retrieved 29 April 2016. Livermore, David ...
Inhibitors include bestatin and cilastatin. Dipeptidase 1 (DPEP1) Dipeptidase 2 (DPEP2) Dipeptidase 3 (DPEP3) Campbell, B.; Lin ...
Imipenem/cilastatin may be an alternative *^ For treatment of chronic pulmonary aspergillosis, histoplasmosis, sporotrichosis, ... Imipenem/cilastatin is an alternative, except for acute bacterial meningitis, where meropenem is preferred ...
Meropenem is stable to mammalian dehydropeptidases and does not require co-administration of cilastatin. It was approved for ... Edwards SJ, Emmas CE, Campbell HE (2005). "Systematic review comparing meropenem with imipenem plus cilastatin in the treatment ... Discovery and development of imipenem/cilastatin". American Journal of Medicine. 78 (6A): 3-21. doi:10.1016/0002-9343(85)90097- ... and thus is co-formulated with the dehydropeptidase inhibitor cilastatin. Imipenem is available in both intravenous and ...
Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants]". Pathologie-biologie. 37 (5): 485- ...
Unlike imipenem, it is stable to dehydropeptidase-1, so can be given without cilastatin. In 2016 a synthetic peptide-conjugated ...
The imipenem/cilastatin, clindamycin or combinations containing an inhibitor of beta-lactamases (i.e. Augmentin, Unasyn) are ...
Wood GC, Hanes SD, Croce MA, Fabian TC, Bougher BA (2002). "Comparison of ampicillin-sulbactam and imipenem-cilastatin for the ...
To prevent its rapid degradation, imipenem is normally coadministered with cilastatin, an inhibitor of this enzyme. Nicolaou, K ...
These include meropenem, imipenem-cilastatin, doripenem, piperacillin-tazobactam, or ceftazidime or cefepime in combination ... imipenem-cilastatin, doripenem, piperacillin-tazobactam, ciprofloxacin or levofloxacin in combination with metronidazole, or ...
Discovery and development of imipenem/cilastatin". The American Journal of Medicine 78 (6A): 3-21. ISSN 0002-9343. PMID 3859213 ...
The β-lactamase inhibitor Cilastatin provides an instructive example of Simmons-Smith reactivity in natural products synthesis ...
... such as cilastatin. (12) Tandem cyclopropanation/fragmentation is a key step in the synthesis of 12-hydroxyeicosatetraenoic ...
July 2013). "Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of ...
Amikacin Amphotericin B Ceftobiprole Ceftaroline Carbapenems (such as imipenem/cilastatin) - used as drug of last resort for a ...
... meropenem and imipenem/cilastatin), or piperacillin/tazobactam for high-risk patients and amoxicillin-clavulanic acid and ...
Piperacillin/tazobactam Procaine benzylpenicillin Ceftazidimeα Meropenemα Aztreonamα Imipenem/cilastatinα Amikacin Azithromycin ...
... cilastatin MeSH D02.455.426.392.368.533.450 --- hypoglycins MeSH D02.455.426.559 --- hydrocarbons, aromatic MeSH D02.455. ...
Procaine benzylpenicillin Cefotaximeα Ceftazidimeα Imipenem/cilastatinα Azithromycin Chloramphenicol Ciprofloxacin Doxycycline ...
... cilastatin MeSH D10.251.355.325.240 --- crotonic acids MeSH D10.251.355.325.240.240 --- crotonates MeSH D10.251.355.325.300 ...
... much like the imipenem/cilastatin combination) "Comparative antibacterial activity of carbapenems against P. aeruginosa (1)". ...
... cilastatin (INN) cilazapril (INN) cilazaprilat (INN) cilengitide (USAN) cilmostim (INN) cilnidipine (INN) cilobamine (INN) ...
J01DF02 Carumonam J01DH02 Meropenem J01DH03 Ertapenem J01DH04 Doripenem J01DH05 Biapenem J01DH51 Imipenem and cilastatin ...
... imipenem/cilastatin, the first carbapenem 1985 - ofloxacin 1986 - mupirocin 1986 - aztreonam 1986 - cefoperazone/sulbactam 1986 ...
Imipenem/cilastatin/relebactam. References[edit]. *^ a b c d e f g h "Imipenem and Cilastatin". The American Society of Health- ... Imipenem/cilastatin was approved for use in the United States in 1985. Imipenem/cilastatin is indicated for the treatment of ... "Imipenem + Cilastatin". International Drug Price Indicator Guide. Retrieved 8 December 2016.. *^ Hamilton, Richart (2015). ... Imipenem/cilastatin, sold under the brand name Primaxin among others, is an antibiotic useful for the treatment of a number of ...
Imipenem alone is an effective antibiotic and can be given without the cilastatin. Cilastatin itself does not have antibiotic ... Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is an enzyme found in the ... Cilastatin can therefore be combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its ... Thus imipenem/cilastatin, like amoxicillin/clavulanic acid, is a commonly used combination product. Keynan S, Hooper NM, Felici ...
Only one patient developed a seizure while on imipenem/cilastatin. Conclusion: The prescription of imipenem/cilastatin at our ... who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. ... The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The ... There were 29% of the patients who were not started on imipenem/cilastatin empirically. Four patients out of the 29 patients ( ...
Cilastatin. Anti-Infective Agents, Urinary. Anti-Infective Agents. Renal Agents. Anti-Bacterial Agents. Topoisomerase II ... The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment ... A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin ... A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired ...
Imipenem and Cilastatin Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before using imipenem and cilastatin injection,. *tell your doctor and pharmacist if you are allergic to imipenem or cilastatin ... Use imipenem and cilastatin injection exactly as directed. Do not use more or less of it or use it more often than prescribed ... Imipenem and cilastatin injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go ...
Cilastatin, and Relebactam Injection: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Imipenem, Cilastatin, and Relebactam Injection. pronounced as (i mi pen em) (sye la stat in) (rel" e bak tam) ... Imipenem, cilastatin, and relebactam injection may cause side effects. Tell your doctor if any of these symptoms are severe or ... Cilastatin is in a class of medications called dehydropeptidase inhibitors. It works by helping imipenem stay active in your ...
View drug interactions between cilastatin / imipenem and Duration. These medicines may also interact with certain foods or ... Cilastatin / imipenem is in the drug class carbapenems.. *Cilastatin / imipenem is used to treat the following conditions: * ... cilastatin / imipenem. A total of 75 drugs are known to interact with cilastatin / imipenem. ... There were no interactions found in our database between cilastatin / imipenem and Duration - however, this does not ...
Professional guide for Imipenem and Cilastatin. Includes: pharmacology, pharmacokinetics, contraindications, interactions, ... Imipenem and cilastatin Intravenous, Intramuscular (Advanced Reading). Professional resources. *Imipenem and Cilastatin (AHFS ... Primaxin® I.V.: Imipenem 250 mg and cilastatin 250 mg [contains sodium 18.8 mg (0.8 mEq)] [DSC]; imipenem 500 mg and cilastatin ... Injection, powder for reconstitution: Imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg ...
Read the side effects of Imipenem and Cilastatin as described in the medical literature. In case of any doubt consult your ... Imipenem and Cilastatin - Information. Imipenem and Cilastatin is a broad spectrum beta-lactam antibiotic, prescribed for ... Side effect(s) of Imipenem and Cilastatin Read the side effects of Imipenem and Cilastatin as described in the medical ...
... cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 ... Imipenem and Cilastatin for Injection. Cilastatin (250 mg) + Imipenem (250 mg). Powder, for solution. Intravenous. Pfizer. Not ... Imipenem and Cilastatin for Injection USP. Cilastatin (250 mg) + Imipenem (250 mg). Powder, for solution. Intravenous. Sandoz ... Imipenem and Cilastatin for Injection USP. Cilastatin (500 mg) + Imipenem (500 mg). Powder, for solution. Intravenous. Sandoz ...
Imipenem and Cilastatin for Injection; Imipenem and Cilastatin for Injection, USP; Primaxin; RAN-Imipenem-Cilastatin ... Imipenem and Cilastatin - Last updated on July 5, 2020. ©2020 Memorial Sloan Kettering Cancer Center. ...
We investigated the protective effect of cilastatin on cisplatin-induced injury to renal proximal tubular cells. Cilastatin is ... Concomitant treatment with cilastatin reduced cisplatin-induced changes. Cilastatin also reduced the DNA-bound platinum but did ... We investigated the protective effect of cilastatin on cisplatin-induced injury to renal proximal tubular cells. Cilastatin is ... cilastatin did not show any effects on cisplatin-treated HeLa cells. Renal DHP-I was virtually absent in HeLa cells. Cilastatin ...
Cilastatin 500mg solution infusion vials. FREE delivery options available. Trusted service, convenient and safe shopping online ... Imipenem 500mg / Cilastatin 500mg solution infusion vials. Registered UK Online Pharmacy - Prescription item. To purchase this ...
Imipenem and cilastatin is a combination medicine used to treat severe infections of the lower respiratory tract, skin, stomach ... Cilastatin helps imipenem work more effectively by preventing the breakdown of the antibiotic in the kidneys. ... What are the possible side effects of imipenem and cilastatin?. Get emergency medical help if you have signs of an allergic ... Imipenem and cilastatin is injected into a muscle. You may be shown how to use injections at home. Do not self-inject this ...
cilastatin uses with the hilum. this side is also surrounded by fibres ... Cilastatin: prominent of these lobules fluctuated slightly, but the. ... bone caries, and ulcers of the skin, including lupus vul- cilastatin uses cilastatin brand name except by some herb brought ... hence the human malformations which result cilastatin drug class cilastatin moa The retractor for elevating the isthmus is ...
Cilastatin; Imipenem indications, usages and related health products lists ... Cilastatin; Imipenem information about active ingredients, pharmaceutical forms and doses by Jodas Expoim, ... Available forms, composition and doses of Cilastatin; Imipenem:. *Injectable; Injection; Cilastatin Sodium 500 mg; Imipenem 500 ... Find online pharmacy, drugstore, pharma or beauty shop where to order or buy Cilastatin; Imipenem brand or generic online:. ...
Imipenem/Cilastatin Kabi Bejelentkezés szükséges. Imipenem/Cilastatin Kabi. Felhívjuk figyelmét, hogy a magyar jogszabályi ...
Lemibet I.V. information about active ingredients, pharmaceutical forms and doses by Teva, Lemibet I.V. indications, usages and related health products lists
The report generally describes cilastatin sodium, examines its uses, production methods, patents. CILASTATIN SODIUM market ... Cilastatin sodium market forecast. 6. CILASTATIN SODIUM MARKET PRICES. 6.1. Cilastatin sodium prices in Europe. 6.2. Cilastatin ... Cilastatin sodium prices in North America. 6.4. Cilastatin sodium prices in other regions. 7. CILASTATIN SODIUM END-USE SECTOR ... 5. CILASTATIN SODIUM MARKET WORLDWIDE 5.1. General cilastatin sodium market situation, trends. 5.2. Manufacturers of cilastatin ...
Showing metabocard for Cilastatin (HMDB0015535). IdentificationTaxonomyOntologyPhysical propertiesSpectraBiological properties ... Cilastatin. Description. A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, ... Kumon H, Nasu Y, Ohmori H, Kodama H, Konishi Y: [Effects of cilastatin sodium, an inhibitor of dehydropeptidase-I, on human ... Lin JH, Chen IW, Ulm EH: Dose-dependent kinetics of cilastatin in laboratory animals. Drug Metab Dispos. 1989 Jul-Aug;17(4):426 ...
To study the effect of moxifloxacin versus imipenem/cilastatin (hereafter referred to as imipenem) treatment on the mortality ... Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different ...
Active Comparator: Imipenem/cilastatin Drug: Imipenem/cilastatin 1000 mg intravenously every 8 hours for a period of 7 to 14 ... Cilastatin. Anti-Bacterial Agents. Anti-Infective Agents. Protease Inhibitors. Enzyme Inhibitors. Molecular Mechanisms of ... Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative ... A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections (APEKS- ...
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator- ... Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator- ...
Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator- ... Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator- ... This study will evaluate the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) (MK-7655A) compared to ...
To identify and review studies which have sought to define the pharmacokinetics of imipenem and cilastatin in patients ... Total body clearance of cilastatin ranged between 9 and 32 ml/min. Total body clearance of both imipenem and cilastatin was ... Drussano, GL, Standiford, HC 1985Pharmacokinetic profile of imipenem/cilastatin in normal volunteersAm J Med784753Google ... Acute kidney failure Cilastatin Clearance CRRT Haemodialysis Haemofiltration Imipenem Pharmacokinetics This is a preview of ...
  • This property is due to the physico-chemical similarities between membrane dipeptidase (MDP), the compound it is usually set to target, and the bacterial metallo-beta-lactamase carried by the CphA gene Therefore, cilastatin is considered a beta-lactamase inhibitor, not an antibiotic per se. (wikipedia.org)
  • The cholestatic hepatitis attributed to imipenem-cilastatin and the carbapenems is probably immunoallergic and resembles the rare, clinically apparent liver injury that has been linked to penicillins and cephalosporins. (wikipedia.org)
  • The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. (dovepress.com)
  • Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment. (dovepress.com)
  • Only one patient developed a seizure while on imipenem/cilastatin. (dovepress.com)
  • The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. (dovepress.com)
  • The use of imipenem/cilastatin empirically was appropriate in 97.2% (n=69/71) of the cases, and its use postculture in 86% of the cases. (dovepress.com)
  • The prescription of imipenem/cilastatin at our setting was mostly appropriate to what is recommended in the guidelines and the literature, although a few cases could have been managed better. (dovepress.com)
more